DOI: https://doi.org/10.18524/2413-9998.2017.1(35).113519

PHARMACOECONOMICS AS A TOOL TO ENHANCE EFFICENCY OF HEALTH CARE SERVICES

Denys Zakrytov, Navneet Kaur

Анотація


Pharmacoeconomics identifies, measures, and compares the costs and consequences of drug therapy to health care systems and society. This article discusses the principles and methods of pharmacoeconomics and how they can be applied to clinical pharmacy practice, and thereby how they can assist in the valuation of pharmacotherapy and other modalities of treatment in clinical practice. By understanding the principles, methods, and application of pharmacoeconomics, health care professionals will be prepared to make better, more informed decisions regarding the use of pharmaceutical products and services.


Ключові слова


pharmacoeconomics; pharmacotherapy; cost; consequences; pharmaceutical care

Повний текст:

Без заголовку (English)

Посилання


Sanchez L. A. Expanding the pharmacist's role in pharmacoeconomics : How and why? Pharmacoeconomics, 1994, № 5, рр. 367–375.

Townsend R. J. Post-marketing drug research and development. Pharmacother, 1987.

Drummond M. , Smith G. T, Wells N. Economic Evaluation in the Development of Medicines. London : Office of Health Economics, 1988.

Lee J. T, Sanchez L. A. Interpretation of “cost-effective” and soundness of economic evaluations in the pharmacy literature. Am J Hosp Pharm, 1991.

Bootman J. L. Pharmacoeconomics and outcomes research. Am J Health Syst Pharm, 1995, pp. 16-19.

Hepler C. D, Strand L. M. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm, 1990.

Eisenberg J. M. Clinical economics : A guide to economic analysis of clinical practices. JAMA, 1989.

Bootman J. L, Townsend R. J, McGhan W.F. Principles of Pharmacoeconomics, 3rd ed. Cincinnati, OH: Harvey Whitney Books, 2005.

Freund D. A, Dittus R. S. Principles of pharmacoeconomic analysis of drug therapy. Pharmacoeconomics, 1992, pp. 20–32.

Barner J, Rascati K. Cost-benefit analysis. In Grauer D, Lee J, Odom T, et al., eds. Pharmacoeconomics and Outcomes, 2nd ed. Kansas City, MO : American College of Clinical Pharmacy, 2003, pp. 115–132.

Blumenschein K., Johannesson M. Use of contingent valuation to place a monetary value on pharmacy services : An overview and review of the literature. Clin Ther, 1999, pp. 1402–1417.

Glossary of terms used in pharmacoeconomic and quality of life analysis. Pharmacoeconomics, 1992.

Detsky A.S., Nagiie I.G. A clinician's guide to cost-effectiveness analysis. Ann Intern Med, 1990, pp. 147–154.

Kozma C. M., Reeder C.E., Schulz R.M. Economic, clinical, and humanistic outcomes : A planning model for pharmacoeconomic research. Clin Ther, 1993, pp. 1121–1132.

Bungay K. M, Sanchez L. A. Types of economic and humanistic outcomes assessments. In Grauer D, Lee J, Odom T, et al., eds. Pharmacoeconomics and Outcomes, 2nd ed. Kansas City, MO : American College of Clinical Pharmacy, 2003, pp. 18-60.

Draugalis J. R., Bootman L. J., Larson L. N., McGhan W.F. Current Concepts : Pharmacoeconomics. Kalamazoo, M I : Upjohn, 1989.

Drummond M. F., Stoddart G. L., Torrance G. W. Methods for the Economic Evaluation of Health Care Programmes, 2nd ed. Oxford : Oxford University Press, 1997.

McGhan W. F. Pharmacoeconomics and the evaluation of drugs and services. Hosp Formul, 1993; pp. 365–378.

Rice D. P., Fox P. J., Max W., et al. The economic burden of Alzheimer's disease care. Health Affairs, 1993, № 12(2), pp. 164–176.

Ernst R. L., Hay J. W. The U.S. economic and social costs of Alzheimer's disease revisited. Am J Public Health, 1994, № 84, pp.1261–1264.

American Diabetes Association. Diabetes Care, 2003, № 26, pp. 917–932.

Stoller M. K. Economic effects of insomnia. Clin Ther, 1994, № 16, pp. 873–897.

Wahlqvist P., Reilly M.C., Barkun A. Systematic review : the impact of gastro-oesophageal reflux disease on work productivity. Aliment Pharmacol Ther, 2006, № 24, рр. 259–272.

American Gastroenterological Association. Burden of Gastrointestinal Diseases. American Gastroenterological Association, 2001.

Sanchez L. A., Lee J.T. Use and misuse of pharmacoeconomic terms. Top Hosp Pharm Manage, 1994, № 13, рр. 11–22.


Пристатейна бібліографія ГОСТ


  1. Sanchez L. A. Expanding the pharmacist's role in pharmacoeconomics : How and why? Pharmacoeconomics, 1994, № 5, рр. 367–375.
  2. Townsend R. J. Post-marketing drug research and development. Pharmacother, 1987. 
  3. Drummond M. , Smith G. T, Wells N. Economic Evaluation in the Development of Medicines. London : Office of Health Economics, 1988. 
  4. Lee J. T, Sanchez L. A. Interpretation of “cost-effective” and soundness of economic evaluations in the pharmacy literature. Am J Hosp Pharm, 1991. 
  5. Bootman J. L. Pharmacoeconomics and outcomes research. Am J Health Syst Pharm, 1995, pp. 16-19. 
  6. Hepler C. D, Strand L. M. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm, 1990. 
  7. Eisenberg J. M. Clinical economics : A guide to economic analysis of clinical practices. JAMA, 1989. 
  8. Bootman J. L, Townsend R. J, McGhan W.F. Principles of Pharmacoeconomics, 3rd ed. Cincinnati, OH: Harvey Whitney Books, 2005. 
  9. Freund D. A, Dittus R. S. Principles of pharmacoeconomic analysis of drug therapy. Pharmacoeconomics, 1992, pp. 20–32. 
  10. Barner J, Rascati K. Cost-benefit analysis. In Grauer D, Lee J, Odom T, et al., eds. Pharmacoeconomics and Outcomes, 2nd ed. Kansas City, MO : American College of Clinical Pharmacy, 2003, pp. 115–132. 
  11. Blumenschein K., Johannesson M. Use of contingent valuation to place a monetary value on pharmacy services : An overview and review of the literature. Clin Ther, 1999, pp. 1402–1417. 
  12. Glossary of terms used in pharmacoeconomic and quality of life analysis. Pharmacoeconomics, 1992. 
  13. Detsky A.S., Nagiie I.G. A clinician's guide to cost-effectiveness analysis. Ann Intern Med, 1990, pp. 147–154. 
  14. Kozma C. M., Reeder C.E., Schulz R.M. Economic, clinical, and humanistic outcomes : A planning model for pharmacoeconomic research. Clin Ther, 1993, pp. 1121–1132. 
  15. Bungay K. M, Sanchez L. A. Types of economic and humanistic outcomes assessments. In Grauer D, Lee J, Odom T, et al., eds. Pharmacoeconomics and Outcomes, 2nd ed. Kansas City, MO : American College of Clinical Pharmacy, 2003, pp. 18-60. 
  16. Draugalis J. R., Bootman L. J., Larson L. N., McGhan W.F. Current Concepts : Pharmacoeconomics. Kalamazoo, M I : Upjohn, 1989. 
  17. Drummond M. F., Stoddart G. L., Torrance G. W. Methods for the Economic Evaluation of Health Care Programmes, 2nd ed. Oxford : Oxford University Press, 1997. 
  18. McGhan W. F. Pharmacoeconomics and the evaluation of drugs and services. Hosp Formul, 1993; pp. 365–378.
  19. Rice D. P., Fox P. J., Max W., et al. The economic burden of Alzheimer's disease care. Health Affairs, 1993, № 12(2), pp. 164–176.
  20. Ernst R. L., Hay J. W. The U.S. economic and social costs of Alzheimer's disease revisited. Am J Public Health, 1994, № 84, pp.1261–1264. 
  21. American Diabetes Association. Diabetes Care, 2003, № 26, pp. 917–932. 
  22. Stoller M. K. Economic effects of insomnia. Clin Ther, 1994, № 16, pp. 873–897. 
  23. Wahlqvist P., Reilly M.C., Barkun A. Systematic review : the impact of gastro-oesophageal reflux disease on work productivity. Aliment Pharmacol Ther, 2006, № 24, рр. 259–272. 
  24. American Gastroenterological Association. Burden of Gastrointestinal Diseases. American Gastroenterological Association, 2001. 
  25. Sanchez L. A., Lee J.T. Use and misuse of pharmacoeconomic terms. Top Hosp Pharm Manage, 1994, № 13, рр. 11–22.




Creative Commons License
Ця робота ліцензована Creative Commons Attribution-NonCommercial 4.0 International License.

ISSN 2413-9998 (Print)
DOI 10.18524/2413-9998